Referencia número: HY-14909

Bardoxolone

(Synonyms: CDDO; RTA 401)

24 Cited Publications

Revisión del cliente

Based on 24 publication(s) in Google Scholar

Bardoxolone (CDDO; RTA 401) is a Nrf2 activator. Bardoxolone shows anti-SARS-CoV-2 3CLpro with IC50 of 27.99 μM. Bardoxolone activates the Nrf2 pathway and inhibits the NF-κB pathway. Bardoxolone can induce cells differentiation, apoptosis and shows antiproliferative activity against cancer cells. Bardoxolone can increase ROS and decrease intracellular GSH levels. Bardoxolone inhibits Z-VAD-FMK (HY-16658B)-induced necroptosis. Bardoxolone can be used for the research of cancer, inflammation and infection, such as SARS-CoV infection and glioblastoma.

Para uso exclusivo en investigación. No vendemos a pacientes.

Pureza: 99.50%
No. CAS: 218600-44-3
Fòrmula: C₃₁H₄₁NO₄
Peso molecular:491.66

Almacenamiento:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 1 year , -20°C, 6 months

Bardoxolone Chemical Structure

No. CAS: 218600-44-3

Tamaño

Precio

Stock

Cantidad

Amount: USD 0.00

* Seleccione Cantidad antes de agregar artículos.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Actividad biológica
- Descripciòn
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- Parmacokinetics
- Ensayo clínico
Chemical Information
Publications (24)
Solvente y solubilidad
- In Vitro
- In Vivo
Protocolo
Pureza y Documentación
Referencias
Help & FAQs
Bioz

Actividad biológica

Descripciòn

IC₅₀ & Target

Nrf-2^[1]

Ver todos los productos específicos de isoformas NF-κB :

Ver todos los productos específicos de isoformas Glutathione Peroxidase :

GPX1
GPX4

Cellular Effect

Cell Line	Type	Value	Description	References
HT-29	EC₅₀	1.3 μM Compound: 7; CDDO	Anti-necroptotic activity in human HT-29 cells assessed as inhibition of TNFalpha/SM-164/Z-VAD-fmk (TSZ)-induced necroptosis by measuring increase in cell viability measured after 12 hrs by celltiter-glo luminescent cell viability assay Anti-necroptotic activity in human HT-29 cells assessed as inhibition of TNFalpha/SM-164/Z-VAD-fmk (TSZ)-induced necroptosis by measuring increase in cell viability measured after 12 hrs by celltiter-glo luminescent cell viability assay	[PMID: 33248849]
L929	EC₅₀	>10 μM Compound: 7; CDDO	Anti-necroptotic activity in mouse L929 cells assessed as inhibition of TNFalpha/Z-VAD-fmk (TZ)-induced necroptosis by measuring increase in cell viability measured after 12 hrs by celltiter-glo luminescent cell viability assay Anti-necroptotic activity in mouse L929 cells assessed as inhibition of TNFalpha/Z-VAD-fmk (TZ)-induced necroptosis by measuring increase in cell viability measured after 12 hrs by celltiter-glo luminescent cell viability assay	[PMID: 33248849]
Macrophage	IC₅₀	0.0004 μM Compound: 4, CDDO	Antiinflammatory activity in mouse macrophages assessed as inhibition of IFN-gamma-induced nitric oxide production after 48 hrs by Griess method Antiinflammatory activity in mouse macrophages assessed as inhibition of IFN-gamma-induced nitric oxide production after 48 hrs by Griess method	[PMID: 23837912]
Macrophage	IC₅₀	0.4 nM Compound: 4, CDDO	Antiinflammatory activity in mouse macrophages assessed as inhibition of IFN-gamma-induced nitric oxide production after 48 hrs by Griess method Antiinflammatory activity in mouse macrophages assessed as inhibition of IFN-gamma-induced nitric oxide production after 48 hrs by Griess method	[PMID: 23837912]
MCF7	IC₅₀	0.16 μM Compound: CDDO (1)	Inhibitory concentration against proliferation of MCF-7 (ER Positive) breast cancer cells Inhibitory concentration against proliferation of MCF-7 (ER Positive) breast cancer cells	[PMID: 15369396]
MCF7	EC₅₀	0.16 μM Compound: CDDO	Cytotoxicity against human MCF7 cells assessed as inhibition of cell proliferation after 3 days by radioactive thymidine incorporation assay Cytotoxicity against human MCF7 cells assessed as inhibition of cell proliferation after 3 days by radioactive thymidine incorporation assay	[PMID: 26177446]
RAW	IC₅₀	0.02 μM Compound: CDDO	Inhibition of nitric oxide production in IFN-gamma stimulated RAW 264.7 cells Inhibition of nitric oxide production in IFN-gamma stimulated RAW 264.7 cells	[PMID: 16996735]
RAW	IC₅₀	20 nM Compound: CDDO	Inhibition of interferon gamma-stimulated NO production in RAW 264.7 cells after 24 hrs Inhibition of interferon gamma-stimulated NO production in RAW 264.7 cells after 24 hrs	[PMID: 17367124]
RAW264.7	IC₅₀	28.3 nM Compound: CDDO	Antiinflammatory activity against IFN-gamma-stimulated mouse RAW264.7 cells assessed as nitrite accumulation after 24 hrs by Griess reagent method Antiinflammatory activity against IFN-gamma-stimulated mouse RAW264.7 cells assessed as nitrite accumulation after 24 hrs by Griess reagent method	[PMID: 20188548]
RAW264.7	IC₅₀	17 nM Compound: CDDO	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of IFN-gamma induced NO production after 24 hrs by Griess reaction Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of IFN-gamma induced NO production after 24 hrs by Griess reaction	[PMID: 21361338]
RAW264.7	IC₅₀	11 nM Compound: CDDO, Bardoxolone	Inhibition of NO production in INFgamma-stimulated mouse RAW264.7 cells measured after 24 hrs by Griess reaction method Inhibition of NO production in INFgamma-stimulated mouse RAW264.7 cells measured after 24 hrs by Griess reaction method	[PMID: 21441026]
RAW264.7	IC₅₀	16.5 nM Compound: CDDO	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of IFNgamma-stimulated NO production pretreated for 2 hrs before IFNgamma challenge measured after 24 hrs by Griess reaction Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of IFNgamma-stimulated NO production pretreated for 2 hrs before IFNgamma challenge measured after 24 hrs by Griess reaction	[PMID: 22533790]
RAW264.7	IC₅₀	23 nM Compound: CDDO	Inhibition of iNOS in LPS-stimulated mouse RAW264.7 cells assessed as inhibition of nitric oxide production after 48 hrs by Griess assay Inhibition of iNOS in LPS-stimulated mouse RAW264.7 cells assessed as inhibition of nitric oxide production after 48 hrs by Griess assay	[PMID: 25965897]

In Vitro

Bardoxolone (30 min) reversibly covalently inhibits SARS-CoV-2 3CLpro with an IC₅₀ of 27.99 ± 2.34 μM and a dissociation constant of 25.90 μM^[1].
Bardoxolone (48 h) inhibits SARS-CoV-2 replication in Vero and Calu-3 cells with EC₅₀ values of 0.43 and 0.42 μM and selective index of 56.6 and 28.2^[1].
Bardoxolone (10-100 nM) induces adipocyte differentiation in 3T3-L1 preadipocytes^[2].
Bardoxolone induces differentiation in acute promyelocytic leukemia cell lines (HL-60, NB4, MR2) and primary AML blasts via PPAR-γ-dependent mechanisms, including enhancement of ATRA-induced effects^[2].
Bardoxolone induces differentiation in osteosarcoma cells via a PPAR-γ-independent mechanism mediated by caspase-8 activity^[2].
Bardoxolone (1-10 μM) exerts antiproliferative and proapoptotic effects in lymphoma and colon cancer cells via inhibition of Lonp1 activity^[2].
Bardoxolone (1-10 μM) induces apoptosis in glioblastoma (U87MG, U251MG) and neuroblastoma (SK-N-MC) cell lines^[2].
Bardoxolone (1-10 μM) induces intrinsic pathway apoptosis in U-937 leukemia cells with increased ROS and decreased intracellular GSH^[2].
Bardoxolone (0.08-10 μM; pre-incubation + 12-16 h) inhibits Z-VAD-FMK (HY-16658B)-induced necroptosis in HT-29 cells with an EC₅₀ of 1.30 ± 0.38 μM^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Parmacokinetics

Species	Dose	Route	CL	CL_unbound	V_ss	T_1/2	F	AUC_0-24
Mice^[1]	0.1 mg/kg	i.v.	0.86 L/h/kg	3.1 L/h/kg	2.4 L/kg	1.9 h	/	/
Mice^[1]	5 mg/kg	p.o.	/	/	/	3.0 h	68 %	/
Rat^[1]	0.1 mg/kg	i.v.	0.72 L/h/kg	/	1.4 L/kg	1.3 h	/	/
Rat^[1]	5 mg/kg	p.o.	/	/	/	4.6 h	87 %	/
Dog^[1]	0.5 mg/kg	i.v.	0.22 L/h/kg	0.59 L/h/kg	1.27 L/kg	4.0 h	/	/
Dog^[1]	5 mg/kg	p.o.	/	/	/	3.7 h	46 %	/
Mice^[1]	0.03 mg/kg	p.o.	/	/	/	/	/	6.94 ng·h/mL

Ensayo clínico

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

No. CAS 218600-44-3
Appearance Solid
Peso molecular 491.66
Fòrmula C₃₁H₄₁NO₄
Color White to off-white
SMILES

CC1(C)CC[C@@]2(C(O)=O)[C@@]([C@](C(C=C3[C@@]4(C)CC[C@]5([H])[C@]3(C)C=C(C#N)C(C5(C)C)=O)=O)([H])[C@@]4(C)CC2)([H])C1
Synonyms

CDDO; RTA 401
Envío

Room temperature in continental US; may vary elsewhere.

Almacenamiento

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	1 year
	-20°C	6 months

Publications (24)

All Cell Imaging/StainingWBRT-PCRCell Proliferation/Viability AssayFlow CytometryIP

Sort by:

Journal Impact Factor

Nature

A pathway coordinated by DELE1 relays mitochondrial stress to the cytosol. [Abstract]

2020 Mar;579(7799):433-437. PMID: 32132706

Bardoxolone purchased from MedChemExpress. Usage Cited in: Nature. 2020 Mar;579(7799):433-437. [Abstract]

Clonal HAP1 knockout and stably reconstituted cells were treated as indicated (CCCP, 20 μM, 9 h; Tunicamycin, HY-A0098, 10 μM, 9 h; Oligomycin (OM), 9 h; CDDO, Bardoxolone, HY-14909, 2.5 μM, 11 h; GTPP, HY-102007A, 10 μM, 11 h) and analysed by immunoblotting.

Bardoxolone purchased from MedChemExpress. Usage Cited in: Nature. 2020 Mar;579(7799):433-437. [Abstract]

HAP1 CHOPNeon cells of the indicated genotypes were treated for 9 h (CCCP, 20 μM; Tunicamycin, HY-A0098, 10 μM; CDDO, Bardoxolone, HY-14909, 2.5 μM) or 12 h (GTPP, HY-102007A, 10 μM) and analysed by flow cytometry. Per genotype and treatment, the CHOPNeonsignal was normalized to its DMSO control and statistical significance is indicated compared to identically treated wild-type cells (mean ± s.d. of n = 3 independent experiments; one-way ANOVA with Dunnett’s multiple comparisons correction).
Cell Mol Immunol

SARS-CoV-2 virus NSP14 Impairs NRF2/HMOX1 activation by targeting Sirtuin 1. [Abstract]

2022 Aug;19(8):872-882. PMID: 35732914

Bardoxolone purchased from MedChemExpress. Usage Cited in: Cell Mol Immunol. 2022 Aug;19(8):872-882. [Abstract]

NRF2/HMOX1 agonists inhibit SARS-CoV-2 replication. Fluorescence microscopy images of SARS-CoV-2 replication in NRF2/HMOX1 agonist-treated Vero-E6 cells. Vero-E6 cells were incubated with SARS-CoV-2 at an MOI of 0.01 for 1 h, and then treated with different NRF2/HMOX1 agonists, namely, Cobalt protoporphyrin (CoPP), Sulforaphane, or Bardoxolone for 24 h.

Bardoxolone purchased from MedChemExpress. Usage Cited in: Cell Mol Immunol. 2022 Aug;19(8):872-882. [Abstract]

NRF2/HMOX1 agonists inhibit SARS-CoV-2 replication. Vero-E6 cells were incubated with SARS-CoV-2 at an MOI of 0.01 for 1 h, and then treated with different NRF2/HMOX1 agonists Bardoxolone (0.3 μM) for 24 h. The viral RNA copy number in the cell culture medium was determined by real-time PCR assay. The results are expressed as the mean ± SD (error bar) of 3 independent experiments; asterisks represent statistical significance based on two-tailed unpaired Student’s t test (*P < 0.05, **P < 0.01)
Chem Eng J

2025 Aug 1.
Proc Natl Acad Sci U S A

Chaperone-mediated autophagy is involved in the execution of ferroptosis. [Abstract]

2019 Feb 19;116(8):2996-3005. PMID: 30718432

Bardoxolone purchased from MedChemExpress. Usage Cited in: Proc Natl Acad Sci U S A. 2019 Feb 19;116(8):2996-3005. [Abstract]

Triterpenoid CDDO inhibits both necroptosis and ferroptosis. HT-22 cells were pretreated with or without 10 μM CDDO (Bardoxolone) or 10 μM Nec-1s for 30 min and then treated with 20 ng/mL TNF-α (T), 20 nM SM-164 (S), and 20 μM zVAD.fmk (Z) for 3, 6, or 9 h. Cell viability was measured by CellTiterGlo assay.

Bardoxolone purchased from MedChemExpress. Usage Cited in: Proc Natl Acad Sci U S A. 2019 Feb 19;116(8):2996-3005. [Abstract]

HT-22 cells were pretreated with 10 μM CDDO (Bardoxolone) and then treated with erastin (10 μM) for 8 h or T/S/Z for 4 h. Cell death was measured by PI uptake assay. Results shown are averages of triplicates ± SEM. **P < 0.01; ***P < 0.001; ****P < 0.0001.

Bardoxolone purchased from MedChemExpress. Usage Cited in: Proc Natl Acad Sci U S A. 2019 Feb 19;116(8):2996-3005. [Abstract]

HT-22 cells were pretreated with or without 10 μM CDDO (Bardoxolone) or 10 μM Nec-1s for 30 min and then treated with 20 ng/mL human TNF-α (T), 20 nM SM-164 (S), and 50 μM zVAD.fmk (Z) for the indicated periods of time. The cell lysates were analyzed by Western blotting using the indicated antibodies.

Bardoxolone purchased from MedChemExpress. Usage Cited in: Proc Natl Acad Sci U S A. 2019 Feb 19;116(8):2996-3005. [Abstract]

CDDO (Bardoxolone) inhibits ferroptosis by blocking GPX4 degradation. HT-22 cells were treated with the indicated stimuli for 6 h, followed by ROS measurement using the fluorescent probe carboxy-H2DCFDA.

Bardoxolone purchased from MedChemExpress. Usage Cited in: Proc Natl Acad Sci U S A. 2019 Feb 19;116(8):2996-3005. [Abstract]

HT-22 cells were treated with the indicated stimuli (10 μM CDDO (Bardoxolone), 10 μM Erastin) for the indicated periods of time. The cell lysates were analyzed by Western blotting using the indicated antibodies.

Bardoxolone purchased from MedChemExpress. Usage Cited in: Proc Natl Acad Sci U S A. 2019 Feb 19;116(8):2996-3005. [Abstract]

HT-29-HA-HSP90-α/β cells were treated with the indicated stimuli (10 μM CDDO (Bardoxolone), 1 μM 17AAG, 10 μM Nec-1s) for 12 h. The cell lysates were analyzed by immunoprecipitation using anti-HA and analyzed by Western blot using the indicated antibodies. Results shown are averages of triplicates ± SEM. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.

Bardoxolone purchased from MedChemExpress. Usage Cited in: Proc Natl Acad Sci U S A. 2019 Feb 19;116(8):2996-3005. [Abstract]

HT22 cells were pretreated with the indicated inhibitors (CDDO (Bardoxolone, HY-14909); T0070907 (HY-13202); Troglitazone (HY-50935 ); TPCA-1 (HY-10074); JAKi; STAT3i; AV-412 (HY-10346); and MK2206 (HY-10358)) and then treated with T/Z, T/S/Z, T/C/Z for 9 h or Glutamate, Erastin (T: 20 ng/ml; Z: 50 μM; S: 20 nM; C: 1 μg/ml; Glutamate: 50 mM; Erastin 10 μM) for 12 h. Cell viability was measured by CellTiterGlo assay.
Acta Pharmacol Sin

Bardoxolone displays potent activity against triple negative breast cancer by inhibiting the TRIP13/STAT3 circuit. [Abstract]

2025 Jun;46(6):1733-1741. PMID: 39939802
Phytomedicine

Oxymatrine alleviates ALD-induced cardiac hypertrophy by regulating autophagy via activation Nrf2/SIRT3 signaling pathway. [Abstract]

2025 Jan 13:138:156389. PMID: 39827815
Free Radic Biol Med

Cigarette smoke disrupts osteogenic-adipogenic balance via Nrf2/HERC2 axis-driven ferroptosis. [Abstract]

2025 Sep 10:S0891-5849(25)00971-2. PMID: 40939850
Biomed Pharmacother

Cyclovirobuxine D alleviates aldosterone-induced myocardial hypertrophy by protecting mitochondrial function depending on the mutual regulation of Nrf2-SIRT3. [Abstract]

2023 Nov:167:115618. PMID: 37793277
J Invest Dermatol

CAMKK2 Defines Ferroptosis Sensitivity of Melanoma Cells by Regulating AMPK‒NRF2 Pathway. [Abstract]

2022 Jan;142(1):189-200.e8. PMID: 34242660
Commun Biol

Druggable genome CRISPR screening identifies the KEAP1/NRF2 axis as a mediator of PD-L1 expression. [Abstract]

2025 Nov 19;8(1):1610. PMID: 41261174
Int J Mol Sci

Triterpenoids CDDO and CDDO-EA Inhibit the Replication of Hepatitis B Virus by Modulating Nucleocapsid Assembly. [Abstract]

2025 Dec 27;27(1):300. PMID: 41516181
Am J Physiol Cell Physiol

Divergent mitochondrial stressors elicit specific retrograde signaling pathways in muscle myotubes. [Abstract]

2026 Jun 1;330(6):C1721-C1736. PMID: 42126081
Molecules

Gastrodin Ameliorates Cognitive Dysfunction in Vascular Dementia Rats by Suppressing Ferroptosis via the Regulation of the Nrf2/Keap1-GPx4 Signaling Pathway. [Abstract]

2022 Sep 24;27(19):6311. PMID: 36234847
iScience

Bradykinin induces acute kidney injury after hypothermic circulatory arrest through the repression of the Nrf2-xCT pathway. [Abstract]

2024 May 22;27(6):110075. PMID: 38868208
Toxins

Role of Nrf2 Nucleus Translocation in Beauvericin-Induced Cell Damage in Rat Hepatocytes. [Abstract]

2022 May 25;14(6):367. PMID: 35737028
Sci Rep

Cyclovirobuxine D protects against diabetic cardiomyopathy by activating Nrf2-mediated antioxidant responses. [Abstract]

2020 Apr 14;10(1):6427. PMID: 32286474
J Pharmacol Exp Ther

CDDO-Me Elicits Anti-Breast Cancer Activity by Targeting LRP6 and FZD7 Receptor Complex. [Abstract]

2020 Apr;373(1):149-159. PMID: 32015160
Viruses

Inhibitors of the Ubiquitin-Mediated Signaling Pathway Exhibit Broad-Spectrum Antiviral Activities against New World Alphaviruses. [Abstract]

2023 Feb 28;15(3):655. PMID: 36992362
J Toxicol

Empagliflozin Alleviates Arsenic Trioxide-Induced Nephrotoxicity by Activating the SIRT1/Akt/Nrf2 Pathway. [Abstract]

2026 Feb 13:2026:5808911. PMID: 41695613
J Cancer Res Clin Oncol

GLRX inhibition enhances the effects of geftinib in EGFR-TKI-resistant NSCLC cells through FoxM1 signaling pathway. [Abstract]

2019 Apr;145(4):861-872. PMID: 30661098
Adv Redox Res

Inhibition of smooth muscle phenotypic modulation by bardoxolone methyl, omaveloxolone, and cinnamaldehyde is Nrf-2 dependent. [Abstract]

2026 Mar:18:100158. PMID: 41891110
Biochem Biophys Res Commun

Bardoxolone treatment alleviates lipopolysaccharide (LPS)-induced acute lung injury through suppressing inflammation and oxidative stress regulated by Nrf2 signaling. [Abstract]

2019 Aug 13;516(1):270-277. PMID: 31248593
Research Square Preprint

2023 Oct 12.
Evid Based Complement Alternat Med

Protective Effect of Simplicillium sp. Ethyl Acetate Extract against High Glucose-Induced Oxidative Stress in HUVECs. [Abstract]

2020 Aug 15;2020:5172765. PMID: 32879632

Solvente y solubilidad

In Vitro:

DMSO : 100 mg/mL (203.39 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.0339 mL

10.1696 mL

20.3393 mL

5 mM

0.4068 mL

2.0339 mL

4.0679 mL

10 mM

0.2034 mL

1.0170 mL

2.0339 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Calculadora de molaridad

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculadora de dilución

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (5.08 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (5.08 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Protocolo

Animal Administration^[3]^[4]

Monkeys^[3]
Two separate studies are conducted in cynomolgus Monkeys. In one, cynomolgus Monkeys (n=9 per sex/dose group) are orally administered Bardoxolone methyl at 5, 30, and 300 mg/kg once daily for 12 months, with an interim analysis at 6 months and a postdose recovery analysis 4 weeks after the final dose, in a GLP environment. In a second study, female cynomolgus Monkeys (n=6 for vehicle and n=12 for treatment) are administered Bardoxolone methyl (30 mg/kg per day), as above, once daily for 28 days.
Mice^[4]
Male C57BL/6J mice are used. After 1 week of acclimatisation to the institutional animal facility (temperature 22°C, 12 h light/dark cycle), the animals are divided into three groups (n=7): (1) mice fed a normal diet (LFD group); (2) mice fed a high-fat diet (HFD group) (40% fat); and (3) mice fed the same HFD and supplemented with BARD in drinking water (10 mg/kg body weight) (HFD/BARD group). The dose and oral administration of BARD are chosen. After 21 weeks, all mice are euthanized using CO2 asphyxiation. Part of the mesenteric fat mass in each animal is collected and stored at −80°C for Western blot analysis. Another portion of the mesenteric fat depot is fixed in 4% paraformaldehyde and embedded in paraffin for the determination of morphology and immunohistochemistry.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Pureza y Documentación

Select Batch:

Pureza: 99.98%

Assay: 99.98%

ee.: 99.98%

Ficha de datos (283 KB)
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Portuguese - PT (396 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instrucciones de manejo (2659 KB)

Referencias

[1]. Sun Q, et al. Bardoxolone and bardoxolone methyl, two Nrf2 activators in clinical trials, inhibit SARS-CoV-2 replication and its 3C-like protease. Signal Transduct Target Ther. 2021 May 29;6(1):212. [Content Brief]

[2]. Borella R, et al. Synthesis and Anticancer Activity of CDDO and CDDO-Me, Two Derivatives of Natural Triterpenoids. Molecules. 2019;24(22):4097. Published 2019 Nov 13. [Content Brief]

[3]. Wang Y, et al. Discovery of bardoxolone derivatives as novel orally active necroptosis inhibitors. Eur J Med Chem. 2021;212:113030. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.0339 mL	10.1696 mL	20.3393 mL	50.8481 mL
	5 mM	0.4068 mL	2.0339 mL	4.0679 mL	10.1696 mL
	10 mM	0.2034 mL	1.0170 mL	2.0339 mL	5.0848 mL
	15 mM	0.1356 mL	0.6780 mL	1.3560 mL	3.3899 mL
	20 mM	0.1017 mL	0.5085 mL	1.0170 mL	2.5424 mL
	25 mM	0.0814 mL	0.4068 mL	0.8136 mL	2.0339 mL
	30 mM	0.0678 mL	0.3390 mL	0.6780 mL	1.6949 mL
	40 mM	0.0508 mL	0.2542 mL	0.5085 mL	1.2712 mL
	50 mM	0.0407 mL	0.2034 mL	0.4068 mL	1.0170 mL
	60 mM	0.0339 mL	0.1695 mL	0.3390 mL	0.8475 mL
	80 mM	0.0254 mL	0.1271 mL	0.2542 mL	0.6356 mL
	100 mM	0.0203 mL	0.1017 mL	0.2034 mL	0.5085 mL

Bardoxolone

24 Cited Publications

100 mg Obtener un presupuesto

Subscribe to the

MedChemExpress

Newsletter

Nombre del producto:
Referencia número:
Cantidad:
MCE Japan Authorized Agent:

Nombre del producto:
No. CAS:
Species:
Pureza:
Cantidad:

Bardoxolone

Anti-Infection Compound Library

Apoptosis Compound Library

Immunology/Inflammation Compound Library

Metabolism/Protease Compound Library

NF-κB Signaling Compound Library

Stem Cell Signaling Compound Library

Anti-Cancer Compound Library

Clinical Compound Library

Antiviral Compound Library

Anti-Aging Compound Library

Drug Repurposing Compound Library

Covalent Screening Library

Antioxidant Compound Library

Differentiation Inducing Compound Library

Oxygen Sensing Compound Library

Ferroptosis Compound Library

Medicine Food Homology Compound Library

Pyroptosis Compound Library

Orally Active Compound Library

Anti-Breast Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Anti-Obesity Compound Library

Transcription Factor-Targeted Library

Targeted Diversity Library

Anti-Liver Cancer Compound Library

Rare Diseases Drug Library

Antidepressant Compound Library

Human Metabolite Library

Anti-Prostate Cancer Compound Library

Anti-Pulmonary Fibrosis Compound Library

Cuproptosis Compound Library

Cancer Stem Cells Compound Library

Pain-Related Compound Library

Metabolic Enzyme Compound Library

Mitochondrial Toxicity Compound Library

Cell Death Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Radioprotector Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Covalent Screening Library Plus

Drug Repurposing Compound Library Plus

Clinical Compound Library Plus

Bioactive Compound Library

Anti-Fibrosis Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

Lactylation Compound Library

Publications Citing Use of MedChemExpress (MCE) Bardoxolone

Ver todos los productos específicos de isoformas NF-κB

Ver todos los productos específicos de isoformas Glutathione Peroxidase

Actividad biológica

Chemical Information

Publications (24)

Solvente y solubilidad

Protocolo

Pureza y Documentación

Referencias

Help & FAQs

Complete Stock Solution Preparation Table

Bardoxolone Related Classifications

Referencia número: HY-14909